EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)
NCT ID: NCT07267624
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
170 participants
INTERVENTIONAL
2026-01-05
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Duration of Antibiotic Treatment for Early VAP (DATE) Trial
NCT01994980
Use of a Rapid Diagnostic Test for Antibiotic De-escalation in Severe Community Acquired Pneumonia
NCT04781829
Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
NCT03409679
An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care
NCT06301841
HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies
NCT05060718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Care in the control group is based on international guidelines for the management of VAP and carried out in accordance with the local guidelines of each center. This includes respiratory samples with traditional cultures to identify pathogens associated with VAP.
No interventions assigned to this group
Intervention Group
In the intervention arm, in addition to traditional cultures for identifying pathogens and their resistance, multiplex PCR will be performed on the patient's respiratory samples. Empirical antibiotic therapy will be directly adapted to the results of multiplex PCR according to the guidelines provided.
PCR multiplex BioFire Pneumonia plus
In the intervention arm, in addition to traditional cultures for identifying pathogens and their resistance, multiplex PCR will be performed on the patient's respiratory samples. Empirical antibiotic therapy will be directly adapted to the results of multiplex PCR according to the guidelines provided.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCR multiplex BioFire Pneumonia plus
In the intervention arm, in addition to traditional cultures for identifying pathogens and their resistance, multiplex PCR will be performed on the patient's respiratory samples. Empirical antibiotic therapy will be directly adapted to the results of multiplex PCR according to the guidelines provided.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours
* Administration of antimicrobial therapy for suspected VAP at the time of inclusion.
* Expected survival \> 96 hours.
Exclusion Criteria
* Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioMérieux
INDUSTRY
Hospital Fribourg, Switzerland
UNKNOWN
Hôpital universitaire de Lausanne
UNKNOWN
Hospital of Neuchâtel
UNKNOWN
Centre Hospitalier du Centre du Valais
OTHER
Hospital Lugano
UNKNOWN
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christophe Le Terrier
Investigator coordinator and Attending Physician in ICU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospitals of Geneva, Division of Intensive Care
Geneva, Canton of Geneva, Switzerland
Dept. of Intensive Care Medicine, University hospital of Lausanne
Lausanne, , Switzerland
Division of Intensive care, Hospital of Lugano
Lugano, , Switzerland
Division of Intensive care, Hospital of Neuchâtel
Neuchâtel, , Switzerland
Division of Intensive care, University hospital of Sion
Sion, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marie-Eve Brunner, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC N° 2024-00369
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.